Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Repros Therapeutics Inc. (RPRX) Message Board

Repros Therapeutics (RPRX) Product Candidate FDA-Review Time

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 35
Posted On: 04/02/2015 4:39:41 AM
Posted By: riddock57
Shares of Repros Therapeutics Inc. (RPRX) soared more than 20% Wednesday in extended-hours trading after the company said that the New Drug Application (NDA) for its enclomiphene citrate product candidate has been accepted by the U.S. Food and Drug Administration (FDA), indicating that the application is sufficiently complete to permit a substantive review.

The NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.

RPRX is developing this product candidate, formerly known as Androxal(R), for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.

RPRX focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders

More about Repros Therapeutics Inc. (RPRX) at www.reprosrx.com

**

After the closing bell on Wednesday, Micron Technology, Inc. (MU) delivered better-than-expected numbers in its quarterly financial results.

For its second quarter fiscal 2015, MU posted revenues of $4.17 billion, a 1% increase year over year, and non-GAAP net income of $941 million, or $0.81 per diluted share, topping the Capital IQ Consensus Estimate of $0.72 earnings per share on revenues of $4.15 billion for the period

MU is a global leader in advanced semiconductor systems. MU‘s broad portfolio of high-performance memory technologies—including DRAM, NAND and NOR Flash—is the basis for solid state drives, modules, multichip packages and other system solutions.

More about Micron Technology, Inc. (MU) at www.micron.com

**

Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.

It has recently included the City of Chino, CA ( www.chino.crwe-pr.com ) into the CRWE Network.

Chino is located in San Bernardino County, California, about 35 miles east of Los Angeles and 25 miles northeast of Anaheim.

The City of Chino had an estimated population in 2013 (U.S. Census Bureau) of 80,988, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally

The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.

The company’s division CRWE Tube ( www.crwetube.com ) is expected to be integrated in all the CRWE Network

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer


(0)
(0)




Repros Therapeutics Inc. (RPRX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us